Thank we Officer, Carol detailed the financial you comments joining. of And morning, that my name Thank Chief statements. our for is results miss glad a third all My you following didn't I'm important XXXX. forward-looking the hear Lisa very this to will Conte. key opportunity provide of Lizak, Financial much. very recap for the quarter
XXXX third of we're that that Although quarter increased the of say in preempt pleased to report I the to Carol will net revenue second X% XXXX. versus quarter
was with therapy. specialty Mytesi, the to the adults fast our crofelemer, takeaway a from time. track momentous noninfectious under by is of on The FDA. a hopefully, opportunity reviewed FDA-approved most this It very the Specialty antiretroviral the important HIV/AIDS expand regarding of today's the important in is indication time from momentum indication product, indication. a for and Jaguar current webcast trade However, priority name potential current diarrhea is living
And treatment the the with receiving much standard expand the we're adult looking for relatively patients in into targeted and United diarrhea to indication a States. much with preventative small more of it's tumors So chemotherapy. therapy need or without in frankly, neglected solid cancer profound potentially larger
Top our the this III OnTarget trial expected of corner. is to crofelemer investigating the efficacy which trial, to from and referred as line safety pivotal so indication Thanksgiving, XXXX, before be Phase around literally results for are Thanksgiving out
This we is also preventative to of indication studying an refer as treatment overactive chemotherapy-induced trial bowel.
chronic of stools vomiting, such heard ever you've the systems and nausea overactive pain neuropathy, as If unpredictable induced debilitating chemotherapy-induced and/or chemotherapy-induced includes loose chemotherapy, diarrhea, or and bowel, which watery urgency. term and
dignity, patient crofelemer potential represents patient the believe eventually of life of And diarrhea associated a the action, can that's and We diarrhea, quality treating patient comfort, very people preventing with crofelemer. in patient in approach ] limiting of expand dramatically these the a cancer of and of treatment terms potential access treatment [ number for new benefit therapy benefit from and way opportunity patients. limiting mechanism cancer that paradigm-shifting to
the metastatic breakthroughs amazing particularly patient patient and in conducting more is years tour cancer voice XX, groups, living X, They're becoming of with targeted been prominent. patient The listening recently population. therapies. I've the longer advocacy XX a metastatic more
the cost learning that therapies to effects life be life. targeted of hearing as So will I'm and what rest from side therapies, at for cancer quality with their of on
survival a patient she severe founder me doubt, a tell of prefer to side yesterday effects. time patient has cancer have of organization shorter her the advocacy less with members would no have most I that
ranked ranked life indicated Journal was to ranked of quality to In higher fact, patients. of of cost that JCO topic than oncology of and past care, a #X Quality survival, higher care. this August published than the patient the was importance higher life than that caregiver practice access survey in
of in are diarrhea of therapies to which FDA What approved, caused patients. many XXX% side More are of cancer some effects? XX targeted XX than these
In Patients want addition, lives live, recognizing suffer cancer cramping, And to the likely just not are nausea, rashes, exist. time, at more. be patients and from same muscle fatigue, itching different. that alopecia, pain, their to neuropathy,
common to an incontinence. day, I be spoke which of one not is happen the with diarrhea. week, diarrhea if every because Anyway, even understanding As feels it it her called she when long example, when Zoom leaves she another almost vulnerable She a used trying has definition activity hers her gain home, of patient when on she's tribe]. her issue, know for along every diaper exercise, doesn't to didn't with causes wear daily diarrhea, when unpredictable She friend to her, should unpredictability which the she a of to particularly leaves she's Anyway, be call. and home. [hiking also walking mentioned a
that and often story I their the be there. to common is cancer, metastatic hear now friend a excuses find However, when reality of can't that not friends face
stinky woman this a happy hike dogs bit had a She got for a don't animal to know So We things. mind story lovers. dog Herman. with, of
the when reality, dogs. Herman. So with with and comfortable she's unpredictability diapers she's patient This is
refer patients studies ask manageable for clinical manageable whom. to toxicities, When
product formulation, our the You trial to can in OnTarget in FDA-approved, from patient that's is The can channels. dose prescription comprises on Mytesi. drug same crofelemer media you quality back the Jaguar's hear that active crofelemer, the life crofelemer available more commercially of and the initiated, podcast the of already which video series social my Mytesi, evaluating is of stories ingredient view same I
is therapies or without criteria focus bring XX, more patients of XX% All therapies. in referred therapies, approved trial tumor as the than XX targeted study of on patient chemotherapy. designed cytotoxic patients patients That number what's agents as the the the of basket This are more benefit solid enrollment to diarrhea with enrolled much than OnTarget a as targeted is who in targeted cause to possible. that targeted population on to
drug file HIV based its results. plan new on the drug application indication. prevention of to new supplemental under is a We drug application application plan a for Mytesi Mytesi. We a in commerce. OnTarget supplemental to cancer diarrhea Mytesi is the therapy-related for already file for new approved
While most new because HIV course, indication. safety Mytesi its or delayed the specialty which chronic has available of for manufacturing United been safety a completed, is issue or And get indication, therefore, approved already applications drug the chronic from of testing is of already is network pharmacies throughout issue, a fail drug, States. and a
of with focused -- we're what results the on Thanksgiving. So before before end line top the
efficacy So activities. trial label expanded is with and what support to of top results the expanded we're educational line promotional potential OnTarget on significance of these focused primary a endpoint the statistical and
of second regions. formulation to it's and indications today's proof-of-concept second distinct trials and East, the we're which from as oral webcast, disease. short to microvillus U.S., I'm continents, to takeaway, refer studies liquid SBS clinical for crofelemer Mytesi. disease Jaguar administration as bowel to as of for me is the Europe that different syndrome, It's rare inclusion distinct different with refer MID, congenital diarrheal is going supporting the these Middle on Africa key a to and supporting intestinal going key crofelemer, and North brings I'm solution, X investigator-initiated which that disorder is a for powder of failure, of takeaway formulation And product. a This investigator IND a
XXXX. failure, expect of for the Crofelemer Medicines European have has the we MVID on called third-party and FDA drug with the the by proof-of-concept corner. proof-of-concept EMA intestinal SBS Agency, granted year orphan of the from which beginning coming and continents different and data been designation the Again, between and around X to the is studies different both X just end
XXXX. is access often we're data such program, access does European accordance in In of United and a clinical or program, looking by reimbursed targeting to from MVID exist early we're And the with patient these patient the published access support for This the guidelines reimbursed the not SBS States. catastrophic could investigations program countries, specific late and/or crofelemer conditions. -- lifelong early that early patient
intensive By program. through to a advantage MVID while in forming able a put disease in this especially infant to going is in be product we've of severe, Therapeutics is footprint take a Napo full Europe the XXXX opportunity global development in commercial ultra-rare Italy, are aware characterized There by every any and developments single drug or in treatments management malabsorption, base parenteral line for MVID. failure, approved diarrhea, of agents instability, requiring for that we're bottom no day. therapeutic support fluid currently other intestinal nutritional acid
days life, day, parenteral I cetera. up opportunity a infections might typically due feet a hours of or and be week, enough could could due mentioned. there's proteins, patients also as to an significant not less. it a XX situation, situation, be this end patients et X accident. due could gut for Intestinal situation vitamins, afflicts carbs, on absolutely And minerals, that failure complications. the These bowel This with syndrome is mortality feet person, bowel short catastrophic as from need about these the normal a million high of to $X is up short to often morbidity, intervention unfortunately, expense. typical take X cost to well. be intestinal In short a can XX absorb patients to a daily congenital for million an area IV It catastrophic and In a nutrients health to syndrome a resulting care high patients, XX, $X.X It bowel surface has high it surgery, for and complications. be year nutrition the reasons,
to percentage benefits nutrition care, able growth parenteral to a the called approved the of now about the attempting reduced It's decrease patients. to well of been a is do is XX%. in bit, syndrome, of basically endpoint. hit the have that growth endpoint which And product is the regulatory crofelemer category about accepted by There you're small is a you XX% find grow with XX% and What to its in or utilized antisecretory be hormone. for of not bowel to dual as everything agent looking so we're to formation. secretions where an regulatory And we've a need parenteral it's that short pipeline teduglutide. in for gut XX% hormone, as nutrition this novel the decreasing in category by It's where a standard can
like As intestinal also approach, a When syringe short case failure. go in benefit we several but right like there different in back ], functioning, you comes the out. goes fully gut, can intact, growth what a they intact, imagine, which no the fully is hormone it's where is diarrheal to [ congenital not with in, MVID. the a gut The is is situation but disorders gut have
growth approach. nothing there's of to grow. benefit There's hormone So no a
other growth limitations approach. the hormone there's And with
hormone. typically crofelemer risk for these need bowel disease, patient for recovering of XX have of adaptation of seems or many growth example, broadly, is some For to the Hyperproliferative Crofelemer growth abnormal care be due cancer the want intact a gut, to case Patients where not of become of from these a cancer months be should administrative limitations. looking to patients, intestinal hormone. or they any involves the to the whether XX don't has treatment giving be about syndrome it or bowel XX% which which failure to surgery, the you standard have can't market. it's of We're fully in short
we third-party think easily and about about in XXXX, analogous for situation, on life. are are back market chemotherapy billion But When are effect is for associated about If valued Now if X with cancer with expected to in our prophylactically the that go opposed mentioned, the talking the first nausea therapy. we market are nausea of according I about -- there there to the available. where Agents go important had days therapy-related the at it's that to note back vomiting, their an to rest just and therapies we typically chemotherapy-induced products you research chronic cancer and talk And is market that side half the trial. $X diarrhea cancer agents to prophylaxis vomiting, this is priced for if and targeted iHealthcareAnalyst. diarrhea, that these as cytotoxic used often as Cancer to be chemotherapy-induced generic approved. and OnTarget #X we're patients of is as valued
of taking are life talking in about diarrhea, situation. therapy-related benefit. how often the a that patient's long more We're targeted we're they and a can for situation for chronically When number term profound much of the for and long metastatic the talking rest about a cancer patients prophylaxis therapies
been a tested based. Imodium chronic dose. agents to that The the When or they specifically can't a basis an to and cancer therapy-related at Imodium On can to start is, therapy-related off about diarrhea. these subtherapeutic or cancer the standard are or haven't patient diarrhea or not, therapy it you get subtherapeutic of care believe pharmacy, their Loperamide opioids to opioid-based And opioid Loperamide. dose think take you cancer and and such approved use as go for we for a
being outcome we cancer another you cancer their then about a we're off think in on patient you about when therapy, And talking of to cases, the impact once off the a And one. therapy, taken some on move have go an now to care.
of So you out options. start to run
of the cancer not before why is it One patient a as they're have design OnTarget to regimen, therapy the the trial, adjust the to problem diarrhea. saving regimen cancer address does reasons we of trial their happens, so life because prophylactic
that With different different think are audiences, resonate the different of OnTarget with benefits. there I trial, the study aspects
all than patients care it's are quality patients, the that there's OnTarget in of of First, dignity pharmaceutical can more this, in what important comfort like these of the supportive and about what And industry. goal diarrhea supporting therapy. the the patient aspect preventing be
so who targeted loudly the study. resonates also the cancer to we for therapy therapy-related the that investigator or for to stay without study, cancer their by principal a with as third-party their may opportunity in is that an have Pablo XX% his patients cancer be study is therapy-related are Next, with on cancer diarrhea. patients OnTarget on impact our their fact, chemotherapy patients therapy and outcome authored there more national And something treatment. Okhuysen, than discontinue likely the diarrhea of indicates that mentioned, Dr. And oncologist
it member costs Eric independent of patient Advisory cancer as And of authored a of much a diarrhea-related an that that diarrhea care then Roeland, study Xx Board to reimbursement also organizations. a shows thirdly, take due certainly without compared by there's interest hospital need about for Scientific to Napo third-party the diarrhea patient a to to rehydration, for to with visits the visits office prescriptions, Dr.
benefits, therapy, with They keeping patient So potential cancer and patient of on of importance have cost life, the priority all recognition audiences. these are different these different of different aspects, their important. may quality levels different
work Crofelemer treatment The most that diarrhea age in radically no type by specifically diarrhea. essentially channel chloride We're normalizer. a been chloride channel Crofelemer antisecretory and modulator, has crofelemer. is a normalizes that It's ion gastrointestinal, the mechanism by cancer for is type function. that's of first-in-class therapies targeted cancer changed. is specifically addressed landscape agent therapies gut this the of induces novel. tested of targeted There
a function, I a when And if gut and say situation takes normalizes happens. crofelemer, in patient nothing is normal
on normalizing and an its in in therapy. secretary providing occurs active often abnormally active it's which So benefit situation, in targeted cancer patients
indications are we disease syndrome, When orphan intestinal short diarrheal failure, that with rare get congenital to MVID such as that I associated and diseases described. the bowel of with
to a is XX here chronic billion on mentioned, to comes maintain have a reach parenteral And basis. XXXX. nutrition also according order $X.X to day. And a complications necessary days global demonstrated mortality, has And week, morbidity, The projected to be intervations, report hours patients an of that's bowel third-party in You that complications. $X.X I agent used -- on as these syndrome market a safety value a administration significant short billion Research of X crofelemer, Vision with that the it's reports. expensive those because typically by
our introduce the of a new population. parenteral the this for failure patient So and nutrition care to goal approach standard need is and chronic completely intestinal in to reducing of management
Jaguar Conference. focus is Antonio presentation scientific cancer presentation breast in then December is prestigious a all for Cancer our be out and this where put the month patients, the time ultimately solid the early have on present able tumors, to catalysts conferences for and enrollment data line grand that lung be the at also this participants basket example, upcoming cancer San momentous have liver include trial is able the Annual typically of poster because which Other for ASCO, at trial on, to where May, Cancer pivotal Breast results results patients a accepted Conference, in focusing the cancer is top this been we'll OnTarget which XXXX, which upcoming the December, very in includes
data, plan We to be product diarrhea, having of cancer NDA the in patients file the available track. would regulatory for therapy-related approved and expand pursuing a to Mytesi prophylaxis to indication positive with simultaneously current the With goal achieving the of to we the XXXX. expect approval supplemental to cancer
goal now. are manufacturing right that to We certainly
So and in for It's transformative feel very this I news again, can't indicated recognition thereafter. from value momentum very is it I've time company industry. that in the of very, any we'll that our in say November, and size, that type and line data don't certainly to a the clinical neglective We trial, opportunity of be for that drivers on rich biotech enough bring released flow of has have product pipeline the OnTarget recognition Jaguar. data could clinical and our trial top including continual and can company. shareholders know events approved all there'll we strength be a stakeholders, the need data valuation the already really are this other the the tough a most important the from the and late-stage our some the
lot have any around. a stock. of is traded any We're don't high-volume coming have have news trading structured our currently. deals warrants anybody We that capitalization don't We a up. very in We
benefit position as mentioned, is their what So to in we patients, not all that also it's to, stakeholders comes the I feel like yet the in of life, we're coincident company value about, only well. all for quality as good a have which the the
around end OnTarget expect data of pivotal as segment the Carol be mentioned the I'd I have Q&A another at data a our to you important We webcast. know the hosting the release, do to with the all that corner. not today webcast this of to CFO, will corner, over Before around participating discussion like pivotal I tell hand with Lizak, I we
there? We'll now the to quarter. financial for the third are you move results Carol,
